Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells

Carcinogenesis

Volumn 28, Issue 3, 2007, Pages 713-723

  Fang, Jing ^a   Zhou, Qiong ^a   Shi, Xiang Lin ^a   Jiang, Bing Hua ^a,b  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; FLAVONOID; GLYCOGEN SYNTHASE KINASE 3BETA; LUTEOLIN; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; PROTEIN KINASE B; PROTEIN P21; S6 KINASE; SMALL INTERFERING RNA; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CELL PROLIFERATION; CELL STRAIN LNCAP; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; ANTICARCINOGENIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CYCLIN D1; HUMANS; LUTEOLIN; MALE; MICE; MICE, INBRED BALB C; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 34047110804     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl189     Document Type: Article

References (52)

1. Djavan,B., Waldert,M., Seitz,C. and Marberger,M. (2001) Insulin-like growth factors and prostate cancer. World J. Urol., 19, 225-233.
2. Grimberg,A. and Cohen,P. (2000) Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J. Cell. Physiol., 183, 1-9.
3. LeRoith,D., Werner,H., Beitner-Johnson,D. and Roberts,C.T.,Jr (1995) Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev., 16, 143-163.
4. Fiorelli,G., De Bellis,A., Longo,A., Giannini,S., Natali,A., Costantini,A., Vannelli,G.B. and Serio,M. (1991) Insulin-like growth factor-I receptors in human hyperplastic prostate tissue: characterization, tissue localization, and their modulation by chronic treatment with a gonadotropin-releasing hormone analog. J. Clin. Endocrinol. Metab., 72, 740-746.
5. Cohen,P., Peehl,D.M. and Rosenfeld,R. (1998) Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br. J. Cancer, 78, 554-556.
6. Cohen,P., Peehl,D.M., Lamson,G. and Rosenfeld,R.G. (1991) Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J. Clin. Endocrinol. Metab., 73, 401-407.
7. Cohen,P., Peehl,D.M., Graves,H.C. and Rosenfeld,R.G. (1994) Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J. Endocrinol., 142, 407-415.
8. Grimberg,A. and Cohen,P. (1999) Growth hormone and prostate cancer: guilty by association? J. Endocrinol. Invest., 22, 64-73.
9. Chan,J.M., Stampfer,M.J., Giovannucci,E., Gann,P.H., Ma,J., Wilkinson,P., Hennekens,C.H. and Pollak,M. (1998) Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science, 279, 563-566.
10. Wolk,A., Mantzoros,C.S., Andersson,S.O., Bergstrom,R., Signorello,L.B., Lagiou,P., Adami,H.O. and Trichopoulos,D. (1998) Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study. J. Natl. Cancer Inst., 90, 911-915.
11. Burfeind,P., Chernicky,C.L., Rininsland,F., Ilan,J. and Ilan,J. (1996) Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc. Natl Acad. Sci. USA, 93, 7263-7268.
12. Reinmuth,N., Liu,W., Fan,F., Jung,Y.D., Ahmad,S.A., Stoeltzing,O., Bucana,C.D., Radinsky,R. and Ellis,L.M. (2002) Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin. Cancer Res., 8, 3259-3269.
13. Nickerson,T., Chang,F., Lorimer,D., Smeekens,S.P., Sawyers,C.L. and Pollak,M. (2001) In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res., 61, 6276-6280.
14. Pollak,M.N., Schernhammer,E.S. and Hankinson,S.E. (2004) Insulin-like growth factors and neoplasia. Nature Rev. Cancer, 4, 505-518.
15. Fotsis,T., Pepper,M.S., Aktas,E., Breit,S., Rasku,S., Adlercreutz,H., Wahala,K., Montesano,R. and Schweigerer,L. (1997) Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res., 57, 2916-2921.
16. Huang,Y.T., Hwang,J.J., Lee,P.P., Ke,F.C., Huang,J.H., Huang,C.J., Kandaswami,C., Middleton,E.,Jr and Lee,M.T. (1999) Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. Br. J. Pharmacol., 128, 999-1010.
17. Post,J.F. and Varma,R.S. (1992) Growth inhibitory effects of bioflavonoids and related compounds on human leukemic CEM-C1 and CEM-C7 cells. Cancer Lett., 67, 207-213.
18. Knowles,L.M., Zigrossi,D.A., Tauber,R.A., Hightower,C. and Milner,J.A. (2000) Flavonoids suppress androgen-independent human prostate tumor proliferation. Nutr. Cancer, 38, 116-122.
19. Shi,R.X., Ong,C.N. and Shen,H.M. (2004) Luteolin sensitizes tumor necrosis factor-alpha-induced apoptosis in human tumor cells. Oncogene, 23, 7712-7721.
20. Shi,R.X., Ong,C.N. and Shen,H.M. (2005) Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells. Cancer Res., 65, 7815-7823.
21. Fang,J., Xia,C., Cao,Z., Zheng,J.Z., Reed,E. and Jiang,B.H. (2005) Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J., 19, 342-353.
22. Rochester,M.A., Riedemann,J., Hellawell,G.O., Brewster,S.F. and Macaulay,V.M. (2005) Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther., 12, 90-100.
23. Liu,L.Z., Fang,J., Zhou,Q., Hu,X., Shi,X. and Jiang,B.H. (2005) Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: Implication of chemoprevention of lung cancer. Mol. Pharmacol., 68, 635-643.
24. Resnik,J.L., Reichart,D.B., Huey,K., Webster,N.J. and Seely,B.L. (1998) Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res., 58, 1159-1164.
25. Weber,M.M., Fottner,C., Liu,S.B., Jung,M.C., Engelhardt,D. and Baretton,G.B. (2002) Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer, 95, 2086-2095.
26. Galili,N., Davis,R.J., Fredericks,W.J., Mukhopadhyay,S., Rauscher,F.J.,III, Emanuel,B.S., Rovera,G. and Barr,F.G. (1993) Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nature Genet., 5, 230-235.
27. Rena,G., Guo,S., Cichy,S.C., Unterman,T.G. and Cohen,P. (1999) Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J. Biol. Chem., 274, 17179-17183.
28. Brunet,A., Bonni,A., Zigmond,M.J., Lin,M.Z., Juo,P., Hu,L.S., Anderson,M.J., Arden,K.C., Blenis,J. and Greenberg,M.E. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 96, 857-868.
29. Diehl,J.A., Cheng,M., Roussel,M.F. and Sherr,C.J. (1998) Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev., 12, 3499-3511.
30. Ramljak,D., Calvert,R.J., Wiesenfeld,P.W., Diwan,B.A., Catipovic,B., Marasas,W.F., Victor,T.C., Anderson,L.M. and Gelderblom,W.C. (2000) A potential mechanism for fumonisin B(1)-mediated hepatocarcinogenesis: cyclin D1 stabilization associated with activation of Akt and inhibition of GSK-3beta activity. Carcinogenesis, 21, 1537-1546.
31. Sherr,C.J. and Roberts,J.M. (1999) CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev., 13, 1501-1512.
32. Horinaka,M., Yoshida,T., Shiraishi,T., Nakata,S., Wakada,M., Nakanishi,R., Nishino,H., Matsui,H. and Sakai,T. (2005) Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene, 24, 7180-7189.
33. Brusselmans,K., Vrolix,R., Verhoeven,G. and Swinnen,J.V. (2005) Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J. Biol. Chem., 280, 5636-5645.
34. Jemal,A., Tiwari,R.C., Murray,T., Ghafoor,A., Samuels,A., Ward,E., Feuer,E.J. and Thun,M.J. (2004) Cancer statistics. CA Cancer J. Clin., 54, 8-29.
35. Gupta,S., Hastak,K., Ahmad,N., Lewin,J.S. and Mukhtar,H. (2001) Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc. Natl Acad. Sci. USA, 98, 10350-10355.
36. Wang,S., DeGroff,V.L. and Clinton,S.K. (2003) Tomato and soy polyphenols reduce insulin-like growth factor-I-stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of intracellular signaling pathways involving tyrosine kinase. J. Nutr., 133, 2367-2376.
37. Adhami,V.M., Siddiqui,I.A., Ahmad,N., Gupta,S. and Mukhtar,H. (2004) Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res., 64, 8715-8722.
38. Li,M., Zhang,Z., Hill,D.L., Chen,X., Wang,H. and Zhang,R. (2005) Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res., 65, 8200-8208.
39. Agarwal,R. (2000) Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem. Pharmacol., 60, 1051-1059.
40. Morrissey,C. and Watson,R.W. (2003) Phytoestrogens and prostate cancer. Curr. Drug Targets., 4, 231-241.
41. Stewart,J.R., Artime,M.C. and O'Brian,C.A. (2003) Resveratrol: A candidate nutritional substance for prostate cancer prevention. J. Nutr., 133, 2440S-2443S.
42. Saleem,M., Adhami,V.M., Siddiqui,I.A. and Mukhtar,H. (2003) Tea beverage in chemoprevention of prostate cancer: A mini-review. Nutr. Cancer, 47, 13-23.
43. Singh,R.P. and Agarwal,R. (2004) A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer. Mutat. Res., 555, 21-32.
44. Kobayashi,T., Nakata,T. and Kuzumaki,T. (2002) Effect of flavonoids on cell cycle progression in prostate cancer cells. Cancer Lett., 176, 17-23.
45. Wang,H., Nan,L., Yu,D., Agrawal,S. and Zhang,R. (2001) Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: In vitro and in vivo activities and mechanisms. Clin. Cancer Res., 7, 3613-3624.
46. Zhang,Z., Wang,H., Li,M., Agrawal,S., Chen,X. and Zhang,R. (2004) MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J. Biol. Chem., 279, 16000-16006.
47. Meek,D.W. and Knippschild,U. (2003) Posttranslational modification of MDM2. Mol. Cancer Res., 1, 1017-1026.
48. Liu,G. and Lozano,G. (2005) p21 stability: Linking chaperones to a cell cycle checkpoint. Cancer Cell, 7, 113-114.
49. Gao,N., Flynn,D.C., Zhang,Z., Zhong,X.S., Walker,V., Liu,K.J., Shi,X. and Jiang,B.H. (2004) G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am. J. Physiol. Cell. Physiol., 287, C281-C291.
50. Putz,T., Culig,Z., Eder,I.E., Nessler-Menardi,C., Bartsch,G., Grunicke,H., Uberall,F. and Klocker,H. (1999) Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res., 59, 227-233.
51. Connolly,J.M and Rose,D.P. (1994) Regulation of DU145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop. Prostate, 24, 167-175.
52. Yu,H. and Rohan,T. (2000) Role of the insulin-like growth factor family in cancer development and progression. J. Natl. Cancer Inst., 92, 1472-1489.